Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 198

Sort by

Sort Order Select

Journal Articles

A complementary new drug for PNH

Robert A. Brodsky

Blood (2020) 135 (12): 884–885.

https://doi.org/10.1182/blood.2020004959

Published: 2020

Journal Articles

Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Antonio M. Risitano, MD PhD, Jong Wook Lee, MD PhD, Rosario Notaro, MD, Robert A. Brodsky, MD, Austin Kulasekararaj, MBBS MDMRCP FRCPath, Jaroslaw P. Maciejewski, MD PhD, Mingjun Huang, PhD, Michael Geffner, MD, Peter Browett, BMedSci, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 2226.

https://doi.org/10.1182/blood-2019-124837

Published: 2019

Journal Articles

Rare Germline Mutations in Complement Regulatory Genes Make the Antiphospholipid Syndrome Catastrophic

Shruti Chaturvedi, MBBS, MS, Evan M Braunstein, MD PhD, Xuan Yuan, MD MSc, Hang Chen, Ravi Kumar Alluri, PhD, Michael B. Streiff, MD, Michelle Petri, MD MPH, Mark Crowther, MD MSc, FRCPC, Keith R McCrae, MD, Robert A. Brodsky, MD

Blood (2019) 134 (Supplement_1): 4.

https://doi.org/10.1182/blood-2019-129115

Published: 2019

Journal Articles

A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

Austin Kulasekararaj, MBBS MDMRCP FRCPath, Antonio M. Risitano, MD PhD, Jaroslaw P. Maciejewski, MD PhD, Rosario Notaro, MD, Peter Browett, BMedSci, MBChB, FRACP, FRCPA, Jong-Wook Lee, MD, Mingjun Huang, PhD, Michael Geffner, MD, Robert A. Brodsky, MD

Blood (2019) 134 (Supplement_1): 3514.

https://doi.org/10.1182/blood-2019-124748

Published: 2019

Journal Articles

CD38 Knockout Primary NK Cells to Prevent "Fratricide" and Boost Daratumumab Activity

Yuya Nagai, MD, Meisam Naeimi Kararoudi, PhD DVM, Ezgi Elmas, MS, Marcelo Pereira, Syed Abbas Ali, MD, Philip Hollingsworth Imus, MD, Dean Anthony Lee, MD PhD, Gabriel Ghiaur, MD PhD

Blood (2019) 134 (Supplement_1): 870.

https://doi.org/10.1182/blood-2019-129456

Published: 2019

Journal Articles

Symptomatic Bilirubin Gallstones in Patients with PNH Treated with Eculizumab

David J. Araten, MD, H. Leon Pachter, Robert J Dring, Elliot Newman, Steven M Cohen

Blood (2019) 134 (Supplement_1): 4795.

https://doi.org/10.1182/blood-2019-124571

Published: 2019

Journal Articles

Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from Turkey

Blood (2019) 134 (Supplement_1): 4805.

https://doi.org/10.1182/blood-2019-128743

Published: 2019

Journal Articles

Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma

Sarah K Johnson, PhD, Stephen Burke, PhD, Matthew Henry, M.S., Amy Greenway, Katie Stone, BS, Brian A Walker, PhD, Frits van Rhee, MD PhD, Gareth Morgan, MD

Blood (2018) 132 (Supplement 1): 4466.

https://doi.org/10.1182/blood-2018-99-119241

Published: 2018

Journal Articles

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Weng-Chit Ung, MSc, Kota Sato, MD PhD, Muneyoshi Futami, MD PhD, Arinobu Tojo, MD PhD

Blood (2018) 132 (Supplement 1): 4435.

https://doi.org/10.1182/blood-2018-99-110709

Published: 2018

Journal Articles

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Hilma J. Van Der Horst, MSc, Simone C. Oostindie, MSc, Saskia AGM Cillessen, MSc, Anne T Gelderloos, MSc, Marije B Overdijk, Martine E.D. Chamuleau, MD, Esther C. W. Breij, PhD, Tuna Mutis, PhD

Blood (2018) 132 (Supplement 1): 4179.

https://doi.org/10.1182/blood-2018-99-115886

Published: 2018

Journal Articles

An Alternative Pathway Specific Flow Cytometric Assay to Detect Complement Activation in Atypical Hemolytic Uremic Syndrome (aHUS)

Jia Yu, Xuan Yuan, MD MSc, Kang Zhou, Daniel White, Samuel A. Merrill, MD PhD, Robert A. Brodsky, MD

Blood (2018) 132 (Supplement 1): 3748.

https://doi.org/10.1182/blood-2018-99-119445

Published: 2018

Journal Articles

Influence of Paroxysmal Nocturnal Hemoglobinuria Clone Positivity on Outcome of Childhood Acquried Aplastic Anemia: A Multicenter Center Study

Sule Unal Cangul, Deniz Yilmaz Karapinar, Arzu Yazal Erdem, Husniye Nese Yarali, Hamiyet Hekimci Ozdemir, Fatma Gumruk, MD, Hasan Fatih Cakmakli, MD, Elif Unal Ince, Gul Nihal Nihal Ozdemir, MD, Muge Gokce, MD, Tiraje Celkan, MD, Aysenur Bahadir, Turan Bayhan, MD, Hale Oren, Huseyin Gulen, Funda Tayfun Kupesiz, Mualla Cetin, Namik Ozbek

Blood (2018) 132 (Supplement 1): 5101.

https://doi.org/10.1182/blood-2018-99-118858

Published: 2018

Journal Articles

Pre-Transplant Genetic Susceptibility in Adult Allogeneic Hematopoietic Cell Transplant Recipients: Incidence and Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy

Blood (2018) 132 (Supplement 1): 3401.

https://doi.org/10.1182/blood-2018-99-112041

Published: 2018

Journal Articles

Iron Overload in Patients with Paroxysmal Nocturnal Hemoglobinuria

Kira Lukina, MD PhD, Nina Tsvetaeva, MD PhD, Olga Nikoulina, MD PhD, Elena Sysoeva, MD PhD, Valentin Sinitsyn, MD PhD Professor, Elena Lukina, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2018) 132 (Supplement 1): 1051.

https://doi.org/10.1182/blood-2018-99-114654

Published: 2018

Journal Articles

The Importance of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: A Cohort Study

Mustafa Nuri Yenerel, MD, Simge Erdem, MD, Metban Mastanzade, Meliha Nalcaci

Blood (2018) 132 (Supplement 1): 4876.

https://doi.org/10.1182/blood-2018-99-119480

Published: 2018

Journal Articles

Excellence in PNH in Canada (EPIC): A Single Centre Pilot Project Evaluating Disease Trajectory for PNH Patients Receiving Eculizumab

Michael James Vernon, MD BSc, Kevin H. M. Kuo, MD MSc, FRCPC, Rebecca Leroux, BSc, Christopher J. Patriquin, MD MSc, FRCPC

Blood (2018) 132 (Supplement 1): 4879.

https://doi.org/10.1182/blood-2018-99-112337

Published: 2018

Journal Articles

Bystander Proliferation of Piga-M utated Hematopoietic Progenitor Cells in Acquired Aplastic Anemia Patients Possessing HLA Class I Allele-Lacking Leukocytes

Takeshi Yoroidaka, MD, Kohei Hosokawa, MD PhD, Tatsuya Imi, MD, Takamasa Katagiri, PhD, Fumihiro Azuma, Shinji Nakao, MD PhD

Blood (2018) 132 (Supplement 1): 1308.

https://doi.org/10.1182/blood-2018-99-115623

Published: 2018

Journal Articles

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

Yasutaka Ueda, MD PhD, Hiroyuki Takamori, MD, Jun-Ho Jang, MD PhD, Chezi Ganzel, MD, Saskia Langemeijer, MD PhD, Makiko Osato, MS, Petra Muus, MD PhD, Jong-Wook Lee, MD PhD, Jun-Ichi Nishimura, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2018) 132 (Supplement 1): 2323.

https://doi.org/10.1182/blood-2018-99-111230

Published: 2018

Journal Articles

Novel Human Anti-HLA-Bw4 and B61 Monoclonal Antibodies Kill Malignant B Cells Via CDC/ADCC While Sparing Normal Peripheral Blood Cells

Hiroyuki Takamatsu, MD PhD, Tatsuhiko Ozawa, PhD, Yoshitaka Zaimoku, MD, Akinori Tsuji, MD, Ichiro Hanamura, MD PhD, Junya Kuroda, MD PhD, Hidenori Tanaka, BS, Shintaro Kawai, PhD, Hiroyuki Kishi, PhD, Shinji Nakao, MD PhD

Blood (2017) 130 (Supplement 1): 2069.

https://doi.org/10.1182/blood.V130.Suppl_1.2069.2069

Published: 2017

Journal Articles

Fibrinogen and Clot Structure Is Affected By Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria

Fraser Macrae, BSc, PhD, Polly Bowman, Emma Linton, Barnaby Peacock-Young, Deborah Clarke, MSc, Darren J Newton, PhD, Claire E McKinley, BSc, Kathryn Riley, Nicola Copeland, Louise Arnold, Morag Griffin, Talha Munir, Peter Hillmen, MBChB, PhD, Stephen John Richards, PhD FRCPath, Robert Ariens, BSc, PhD, Anita Hill, MBChB (Hons), PhD

Blood (2017) 130 (Supplement 1): 462.

https://doi.org/10.1182/blood.V130.Suppl_1.462.462

Published: 2017

NARROW

A complementary new drug for PNH

Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Rare Germline Mutations in Complement Regulatory Genes Make the Antiphospholipid Syndrome Catastrophic

A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

CD38 Knockout Primary NK Cells to Prevent "Fratricide" and Boost Daratumumab Activity

Symptomatic Bilirubin Gallstones in Patients with PNH Treated with Eculizumab

Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from Turkey

Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

An Alternative Pathway Specific Flow Cytometric Assay to Detect Complement Activation in Atypical Hemolytic Uremic Syndrome (aHUS)

Influence of Paroxysmal Nocturnal Hemoglobinuria Clone Positivity on Outcome of Childhood Acquried Aplastic Anemia: A Multicenter Center Study

Pre-Transplant Genetic Susceptibility in Adult Allogeneic Hematopoietic Cell Transplant Recipients: Incidence and Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy

Iron Overload in Patients with Paroxysmal Nocturnal Hemoglobinuria

The Importance of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: A Cohort Study

Excellence in PNH in Canada (EPIC): A Single Centre Pilot Project Evaluating Disease Trajectory for PNH Patients Receiving Eculizumab

Bystander Proliferation of Piga-M utated Hematopoietic Progenitor Cells in Acquired Aplastic Anemia Patients Possessing HLA Class I Allele-Lacking Leukocytes

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

Novel Human Anti-HLA-Bw4 and B61 Monoclonal Antibodies Kill Malignant B Cells Via CDC/ADCC While Sparing Normal Peripheral Blood Cells

Fibrinogen and Clot Structure Is Affected By Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only